Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety results from the randomized CARIN trial.

Hegewisch-Becker, S., Lerchenmüller, C.A., Welt, A., Decker, T., Just, M., Steffens, C., Hipper, A., Marschner, N., 2011.

J Clin Oncol (Meeting Abstracts). 2011;29(suppl; abstract 1044). doi: 10.1200/jco.2011.29.15_suppl.1044

Abstract